How to determine the best assessment for your clinical trial design

12 July 2022
digital_pharmacovigilance_trial_doctor_health_remote_big

J C Wilson, product manager for electronic clinical outcome assessment (eCOA) at data analytics firm IQVIA, provides an Expert View on the changing landscape of clinical trial design.

The pandemic revolutionized data collection and patient engagement in clinical trials.

Although the life sciences industry has been historically cautious to adopt emerging technology trends, the sudden shutdown of in-person trial sites in adherence to safety protocols left sponsors and researchers with no choice but to adapt with more agile tools for remote data collection.

Electronic clinical outcome assessments (eCOAs) ultimately emerged as a key asset in the functionality of decentralized clinical trials (DCTs) by providing clinicians, patients, and caregivers with a simple way to record data and insights without ever setting foot in a clinic.

Moving forward, eCOAs will continue to be an integral component of the clinical trial landscape. When deciding on the best COAs to implement, sponsors should consider several factors throughout the design process.

Trial design considerations

While clinician-reported outcomes (ClinROs) and performance outcomes (PerfOs) must be completed by medical professionals, patient reported outcomes (PROs) and observer reported outcomes (ObsROs) are often more subjective in nature, as they are completed by patients and caregivers.

For patients and caregivers to accurately complete these assessments, sponsors must equip them with training and a support structures that may not always be part of the initial trial design.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical